US Brachytherapy Market Size to Reach $1.59 Billion by 2035

US brachytherapy market size reached $0.76 billion in 2025 and is projected to expand to $1.59 billion by 2035, growing at a CAGR of 7.7% during the forecast period (2026–2035). Market growth is supported by rising cancer incidence, increasing adoption of targeted radiation therapies, and healthcare infrastructure investments.

KEY MARKET DRIVERS

• Rising incidence of prostate and breast cancer increasing demand for localized radiation therapies
• Growing adoption of minimally invasive oncology treatment techniques
• Expanding availability of advanced radiation planning systems in hospitals
• Favorable reimbursement policies for radiation-based cancer treatments
• Increasing preference for outpatient cancer care procedures

Browse the full report description of “US Brachytherapy Market Size, Share & Trends Analysis Report by Indication (Breast Cancer, Gynecological Cancer, Prostate Cancer, Skin Cancer, Brain Cancer, and Others), and by Type (Low-Dose Rate (LDR) Brachytherapy and High-Dose Rate (HDR) Brachytherapy), Forecast Period (2026-2035)” Of https://www.omrglobal.com/industry-reports/us-brachytherapy-market

Regional Analysis

The United States accounts for the majority of installed radiation oncology systems in North America. According to national cancer surveillance data, prostate and breast cancers remain among the most diagnosed malignancies, directly supporting sustained demand for internal radiation therapies. Federal healthcare spending trends indicate continued investment in oncology infrastructure through Medicare and Medicaid programs, improving access to brachytherapy in both public and private healthcare facilities. Additionally, the presence of specialized cancer centers and academic research institutions contributes to faster clinical adoption of high-dose-rate and low-dose-rate brachytherapy systems across major metropolitan regions.

Competitive Landscape

Key companies operating in the US brachytherapy market include Elekta AB, Varian Medical Systems, Eckert & Ziegler, IsoRay, BEBIG Medical, Theragenics Corporation, CIVCO Radiotherapy, and Sensus Healthcare. These companies focus on the development and supply of radiation delivery systems, radioactive sources, treatment planning software, and supporting clinical accessories. Market competition is structured around product differentiation in system compatibility, imaging integration, workflow efficiency, and regulatory compliance. Most companies maintain direct relationships with hospital networks and oncology clinics to support equipment installations, maintenance services, and clinical training programs.

Recent Market Developments

• In July 2025, iCAD, Inc. was acquired by RadNet, Inc.’s subsidiary DeepHealth. The acquisition expands DeepHealth’s oncology software portfolio and supports integration of cancer diagnosis and radiation therapy technologies with clinical treatment workflows, including those complementary to brachytherapy.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Indication
  • By Type 
• Competitive Landscape -  Becton, Dickinson and Company (BD), Elekta AB, IsoRay Inc., Theragenics Corp., Varian Medical Systems, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

US Brachytherapy Market Report Segment

By Indication

• Breast Cancer
• Gynecological Cancer
• Prostate Cancer
• Skin Cancer
• Brain Cancer
• Others

By Type 

• Low-Dose Rate (LDR) Brachytherapy
• High-Dose Rate (HDR) Brachytherapy
• Others

To learn more about this report request a sample copy@ https://www.omrglobal.com/request-sample/us-brachytherapy-market